Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook
Rigel Pharmaceuticals shares jumped over 30% to around $38 on Nov. 5, 2025, after reporting Q3 revenue of $69.5 million, up 25% year-over-year. Net income reached $27.9 million, and the company raised its 2025 revenue guidance to $285–$290 million. Product sales, led by Tavalisse, surged 65%. Rigel also announced new clinical milestones and ongoing global partnerships.
